Final Results from Arq 197-209: A Global Randomized Placebo-controlled Phase 2 Clinical Trial of Erlotinib Plus ARQ 197 Versus Erlotinib Plus Placebo in Previously Treated EGER-inhibitor Naive Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

被引：0

作者：

Von Pawel, J. ^{[1
]}

Akerley, W. ^{[2
]}

Brugger, W. ^{[3
]}

Ferrari, D. ^{[4
]}

Garmey, E. ^{[4
]}

Gerber, D. ^{[5
]}

Orlov, S. ^{[6
]}

Ramlau, R. ^{[7
]}

Sequist, L. ^{[8
]}

Schiller, J. ^{[5
]}

机构：

[1] Asklepios Klinikum Gauting, Munich, Germany

[2] Univ Utah, Huntsman Canc Inst, Huntsman Canc Inst Canc Care Program, Salt Lake City, UT USA

[3] Schwarzwald Baar Clin, Schwenningen, Germany

[4] Ar Qule Inc, Woburn, MA USA

[5] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

[6] St Petersburg Pavlov State Med Univ, St Petersburg, Russia

[7] Wielkopolskie Centrum Chorob Pluc & Gruzlicy, Poznan, Poland

[8] Massachusetts Gen Hosp, Boston, MA 02114 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S501 / S501

页数：1

共 50 条

[1] FINAL RESULTS FROM ARQ 197-209: A GLOBAL RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL OF ERLOTINIB PLUS ARQ 197 VERSUS ERLOTINIB PLUS PLACEBO IN PREVIOUSLY TREATED EGFR-INHIBITOR NAiVE PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Sequist, L. V.
Akerley, W. L.
Brugger, W.
Ferrari, D.
Garmey, E.
Gerber, D. E.
Orlov, S.
Ramlau, R.
von Pawel, J.
Schiller, J. H.
ANNALS OF ONCOLOGY, 2010, 21 : 122 - 122
[2] Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Schiller, J. H.
Akerley, W. L.
Brugger, W.
Ferrari, D.
Garmey, E. G.
Gerber, D. E.
Orlov, S. V.
Ramlau, R.
Von Pawel, J.
Sequist, L. V.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
[3] A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC)
Sandler, A.
Schiller, J. H.
Hirsh, V.
Sequist, L. V.
Soria, J.
Von Pawel, J.
Wang, Q.
Pande, A. U.
Schwartz, B. E.
Garmey, E. G.
Gorbatchevsky, I.
Scagliotti, G.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[4] MARQUEE: A randomized, double-blind, placebo-controlled, phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small-cell lung cancer (NSCLC)
Scagliotti, G.
Novello, S.
Ramlau, R.
Favaretto, A.
Barlesi, F.
Akerley, W.
Von Pawel, J.
Shuster, D.
Schwartz, B.
Sandler, A.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S798 - S799
[5] EFFICACY ANALYSIS FOR MOLECULAR SUBGROUPS IN MARQUEE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF TIVANTINIB (ARQ 197) PLUS ERLOTINIB VERSUS PLACEBO PLUS ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC)
Novello, Silvia
Scagliotti, Giorgio
Ramlau, Rodryg
Favaretto, Adolfo
Barlesi, Fabrice
Akerley, Wallace
Von Pawel, Joachim
Orlov, Sergey
Spigel, David R.
Santoro, Armando
Shepherd, Frances
Hirsh, Vera
Sequist, Lecia V.
Shuster, Dale
Zahir, Hamim
Wang, Qiang
Schwartz, Brian
Von Roemeling, Reinhard
Sandler, Allan B.
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S901 - S902
[6] Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Scagliotti, Giorgio
von Pawel, Joachim
Novello, Silvia
Ramlau, Rodryg
Favaretto, Adolfo
Barlesi, Fabrice
Akerley, Wallace
Orlov, Sergey
Santoro, Armando
Spigel, David
Hirsh, Vera
Shepherd, Frances A.
Sequist, Lecia V.
Sandler, Alan
Ross, Jeffrey S.
Wang, Qiang
von Roemeling, Reinhard
Shuster, Dale
Schwartz, Brian
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (24) : 2667 - +
[7] Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
Gerber, D. E.
Socinski, M. A.
Neal, J. W.
Wakelee, H. A.
Shirai, K.
Sequist, L. V.
Rosovsky, R.
Lilenbaum, R.
Bastos, B. R.
Huang, C.
Johnson, M. L.
Hasketh, P. J.
Subramaniam, D. S.
Chai, F.
Kazakin, J.
Schwartz, B. E.
Schiller, J. H.
Brahmer, J. R.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S36 - S36
[8] Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
Scagliotti, Giorgio V.
Krzakowski, Maciej
Szczesna, Aleksandra
Strausz, Janos
Makhson, Anatoly
Reck, Martin
Wierzbicki, Rafal F.
Albert, Istvan
Thomas, Michael
Abrao Miziara, Jose Elias
Papai, Zsolt S.
Karaseva, Nina
Thongprasert, Sumitra
Dalmau Portulas, Elsa
von Pawel, Joachim
Zhang, Ke
Selaru, Paulina
Tye, Lesley
Chao, Richard C.
Govindan, Ramaswamy
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2070 - 2078
[9] Erlotinib Plus Either Pazopanib or Placebo in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: A Randomized, Placebo-Controlled Phase 2 Trial With Correlated Serum Proteomic Signatures
Spigel, David R.
Burris, Howard A., III
Greco, F. Anthony
Shih, Kent C.
Gian, Victor G.
Lipman, Andrew J.
Daniel, Davey B.
Waterhouse, David M.
Finney, Lindsey
Heymach, John V.
Hainsworth, John D.
CANCER, 2018, 124 (11) : 2355 - 2364
[10] Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer
Sequist, Lecia V.
von Pawel, Joachim
Garmey, Edward G.
Akerley, Wallace L.
Brugger, Wolfram
Ferrari, Dora
Chen, Yinpu
Costa, Daniel B.
Gerber, David E.
Orlov, Sergey
Ramlau, Rodryg
Arthur, Susan
Gorbachevsky, Igor
Schwartz, Brian
Schiller, Joan H.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) : 3307 - 3315

← 1 2 3 4 5 →